UK-based vet products group Dechra Pharmaceuticals announced improved annual results for the year to 30 June on Monday and confirmed that its strong momentum has continued into the current financial year.

Annual revenues were GBP608m, compared with GBP515.1m reported for the previous year. Pre-tax profits of GBP74m were up from GBP40.9m in 2020.

The company also announced that its dividend has been increased by 18.1% from GBP0.3429 per share to GBP0.4050 per share.

Dechra said that all product categories are delivering growth, with the CAP (Companion Animal Products) and Equine performance described as 'exceptional'.

Ian Page, the company's chief executive, said: 'Dechra has continued to outperform a robust market throughout the COVID-19 pandemic affected financial year. As we start the new financial year trading remains strong with the momentum and market penetration seen in the second half of the prior financial year continuing.'

(EUR1=GBP0.86)